People · Operator
Named in public records as an officer, director or promoter · active 2020–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Carmot Therapeutics Inc. | — | Biotechnology | Series D+ | $349.8M | $2.4B | 2020 |
Aetna Wun K. Trombley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aetna Wun K. Trombley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Aetna Wun Trombley | 1 | 3 |
| Tim K. Kutzkey | 1 | 1 |
| Magnus K. Persson | 1 | 1 |
| Daniel A. Erlanson | 1 | 1 |
| Dave K. Goeddel | 1 | 1 |
| Anne K. Phillips, M.D. | 1 | 1 |
| Peter K. Svennilson | 1 | 1 |
| Timothy K. Garnett | 1 | 1 |
| Stig K. Hansen, Ph.D. | 1 | 1 |
| Heather K. Turner | 1 | 1 |
| Tim K. Kutzky | 1 | 1 |
| Stig K. Hansen | 1 | 1 |
| Larry K. Lasky | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.